Drug Profile
Insulin - Impel Pharmaceuticals
Alternative Names: INP-102; POD™ insulinLatest Information Update: 27 Apr 2022
Price :
$50
*
At a glance
- Originator Impel NeuroPharma
- Developer Impel Pharmaceuticals
- Class Antidementias; Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 25 Apr 2022 Impel Neuropharma is now called Impel Pharmaceuticals
- 14 Oct 2021 Discontinued - Phase-III for Alzheimer's disease in USA (Intranasal) (Impel NeuroPharma pipeline, October 2021).
- 06 Sep 2018 Phase III development is ongoing for Alzheimer's disease in USA (Impel Neuropharma Pipeline - September 2018)